Clinical Report: FDA expands treatment in nephrotic syndrome
Overview
The FDA has approved obinutuzumab (Gazyva) for reducing relapse risk in patients aged 2 and older with frequently relapsing or steroid-dependent idiopathic nephrotic syndrome. This approval is based on the INSHORE trial, which demonstrated that 73% of patients receiving obinutuzumab met the primary efficacy endpoint compared to standard treatment.
Background
Idiopathic nephrotic syndrome is a significant pediatric kidney disorder characterized by proteinuria, leading to complications such as low albumin levels, high cholesterol, and increased risk of infections and blood clots. The condition predominantly affects children aged 2 to 7 years and has an estimated annual incidence of 1 to 4 cases per 100,000 pediatric patients.
Data Highlights
| Study | Population | Primary Endpoint | Obinutuzumab Efficacy |
|---|---|---|---|
| INSHORE | 85 patients aged 2+ | Urine protein-creatinine ratio ≤0.2 g/g at Week 52 | 73% met endpoint |
Key Findings
- Obinutuzumab is approved for patients aged 2 years and older with frequently relapsing or steroid-dependent idiopathic nephrotic syndrome.
- The INSHORE trial showed a statistically significant greater proportion of patients on obinutuzumab reached the primary efficacy endpoint compared to standard treatment.
- Common side effects of obinutuzumab include infections, infusion-related reactions, and neutropenia.
- The drug carries boxed warnings for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
- Obinutuzumab has previously received Breakthrough Therapy, Orphan Drug, and Priority Review designations.
Clinical Implications
Clinicians should be aware of the potential side effects and the need for monitoring during treatment with obinutuzumab.
Conclusion
The FDA's approval of obinutuzumab provides a new treatment option for managing frequently relapsing or steroid-dependent idiopathic nephrotic syndrome.
Related Resources & Content
- FDA, FDA, 2026 -- FDA Approves Drug to Treat Idiopathic Nephrotic Syndrome in Patients 2 Years and Older
- MDSpire News, MDSpire News, 2026 -- FDA Approval Targets Rare Kidney Disease
- Clinical Kidney Journal, Clinical Kidney Journal, 2026 -- 2025 KDIGO guideline on the management of nephrotic syndrome in children
- MDSpire News — New SLE Treatments Show Promise in Trials
- MDSpire News — New Option for IgA Nephropathy Management
- MDSpire News — Obinutuzumab Boosts Lupus Nephritis Treatment Success
- FDA Approves Drug to Treat Idiopathic Nephrotic Syndrome in Patients 2 Years and Older
- FDA Approval Targets Rare Kidney Disease
- 2025 KDIGO guideline on the management of nephrotic syndrome in children: a comment of the European Renal Association Immunonephrology Working Group | Clinical Kidney Journal | Oxford Academic
- Efficacy of Obinutuzumab for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
